Navigation Links
Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
Date:5/5/2008

NEW ROCHELLE, N.Y., May 5 /PRNewswire/ -- Biotech and pharma companies are increasingly utilizing novel technologies to assess the druggability of test compounds early in the development cycle to avoid costly late clinical-stage attrition, according to Genetic Engineering and Biotechnology News (GEN) (http://www.genengnews.com/). By identifying absorption, distribution, metabolism, excretion, and toxicity (ADMET) issues early, pharma also has the opportunity to increase the probability of success of its new drug development activities and reduce the time to market, reports the May 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2460).

"With new drug development costs estimated at over $1 billion, it's imperative that biotech and pharma firms use ADMET tools intelligently and as early as possible in the drug discovery and development process to get a better handle on costs," notes John Sterling, Editor-in-Chief, GEN. "The intelligent application of ADMET studies could also go a long way to improving clinical trial results."

UCB Pharma, for example, uses a suite of validated assays and protocols to monitor the toxic characteristics of all small molecule compounds in its drug discovery pipeline. The company's in vitro toxicology team relies on cell-based assays to assess the cytotoxic potential of drug candidates using cell lines derived from human and rat hepatocytes.

CeeTox, a contract research organization, also takes a cell-based approach when looking at toxicity potential using a number of different cell models to assess not only hepatocellular-based toxic potential but also cardiotoxicity. The company introduced the use of neonate rat cardiomyocytes cultured in 96-well plates to monitor the potential for cardiotoxicity of a drug candidate.

Other companies covered in the GEN article include Affymetrix, Iconix, Sovicell, Apredica, MatTek, ChanTest, and EggCentris.

For a copy of the May 1, 2008 issue of GEN, please call (914) 740-2122, or e-mail: ebicovny@liebertpub.com

Genetic Engineering and Biotechnology News (http://www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor-in-Chief, GEN, Phone: 914-740-2196, Cell: 646-234-5118, E-mail: jsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering and Biotechnology News
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE genetics Announces First Quarter 2008 Financial Results
2. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
3. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
4. deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information
5. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
6. Genetic Testing for All: QTrait Offers Industrys Least Expensive, Most Secure DNA Tests With TRUSTe Certification
7. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
8. Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
9. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
10. Genetic Engineering and Biotechnology News (GEN) Blog: International Students in the United States - A Diminishing Pool of Talent for Biotech?
11. Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
Breaking Biology News(10 mins):